Abstract
Targeted inhibition of tumor necrosis factor-α (TNF-α) is an effective therapy in rheumatoid arthritis (RA). In some rare cases, autoimmune phenomena, including drug-induced lupus and vasculitis, is described. However, the immunological mechanisms underlying the development of autoimmunity are unknown. We report 3 patients that developed autoimmune phenomena while in use of TNF-α inhibitor, showing concomitant increase in rheumatoid factor (RF). We hypothesize that the increase in RF several months prior to the occurrence of vasculitis may help identifying other patients at risk for the development of vasculitis secondary to these medications.
This is a preview of subscription content, log in via an institution to check access.
References
Srivastava MD, Alexander F, Tuthill RJ (2005) Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 61:329–336
Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86:242–251
Day R (2002) Adverse reactions to TNF-α inhibitors in rheumatoid arthritis. Lancet 359:540–541
Shakoor N, Michalska M, Harris C, Block J (2003) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579–580
Seo SJ, Fields ML, Buckler JL et al (2002) The impact of T helper and T regulatory cells on the regulation of anti-double stranded DNA B cells. Immunity 16:535–546
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285
Jarrett SJ, Cunnane G, Conaghan PG et al (2003) Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30:2287–2291
Flendrie M, Vissers WH, Creemers MC et al (2005) Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 7:666–676
Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM (2005) Clinical approach to cutaneous vasculitis. Curr Opin Rheumatol 17:56–61
Day R (2002) Adverse reactions to TNF-a inhibitors in rheumatoid arthritis. Lancet 359:540–541
Vermeire S, Norman M, Van Assche G et al (2003) Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 125:32–39
Shakoor N, Michalska M, Harris C, Block J (2003) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579–580
Turesson C, McClelland RL, Christianson T, Matteson E (2008) Clustering of extraarticular manifestations in patients with rheumatoid arthritis. J Rheumatol 35:179–180
Geirsson AJ, Sturfelt G, Truedsson L et al (1987) Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications. Ann Rheum Dis 46:727–733
Turesson C, Matteson EL (2009) Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol 21:35–40
Acknowledgments
Fundação Apoio À Pesquisa Estado São Paulo-Brasil (FAPESP 2008/02917-0 and 2009/06049-6), Conselho Nacional Pesquisa Desenvolvimento-Brasil CNPq (300447/2009-4).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mendonça, J.A., Marques-Neto, J.F., Samara, A.M. et al. Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis. Rheumatol Int 32, 815–818 (2012). https://doi.org/10.1007/s00296-011-1812-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-1812-3